Trial Profile
A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir/velpatasvir (Primary) ; Voxilaprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms LEPTON
- Sponsors Gilead Sciences
- 01 Oct 2020 Results integrating analysis of three clinical trials (NCT02202980, NCT02613871 and NCT02738333) published in the Hepatology Research
- 27 Jan 2017 Results (n=53) assessing efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks, published in the Gastroenterology
- 27 May 2016 Results published in the Gastroenterology